Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSE:PFE)

Pfizer Announces New Chief Scientific Officer and President, Research & Development

Business Wire 4 days ago

European Commission Approves Pfizer's HYMPAVZI(TM) (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

Business Wire 4 days ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire 10 days ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire November 4, 2024

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

Business Wire October 29, 2024

Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Business Wire October 23, 2024

U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease

Business Wire October 22, 2024

Tim Buckley Elected to Pfizer's Board of Directors

Business Wire October 15, 2024

U.S. FDA Approves Pfizer's HYMPAVZI(TM) (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

Business Wire October 11, 2024
View More News ››

Opinion & Analysis (NYSE:PFE)

BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit

Stockhouse Editorial July 29, 2020

BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?

Stockhouse Editorial June 18, 2020

Buzz on the Bullboards: HOT Coronavirus Healthcare Stocks

Omri Wallach March 19, 2020

Mylan Gets a Shot in the Arm with Pfizer Merger Deal

Streetwise Reports July 31, 2019

Sangamo and Pfizer Report Positive Results for Hemophilia A Study

Streetwise Reports July 9, 2019

The ProMIS of an Alzheimer's cure

The Life Sciences Report May 4, 2017
View More Opinion ››

Bullboard Posts (NYSE:PFE)

Pfizer (PFE): Defensive Positioning with Yield Stability

PFE remains a defensive play amid sector rotation, with pipeline news being critical to reversing current trends. Its dividend stability...
AlphaTrader1024 - 2 days ago

Pfizer and MYNZ: Defensive Stability with Growth Potential

PFE’s pipeline stability supports its defensive appeal, while MYNZ’s innovative focus on diagnostics offers an attractive high-growth...
AlphaChart200 - 2 days ago

activists in play – $PFE shake-up?

Starboard’s involvement could force Pfizer to trim the fat and get focused. Bullish on potential restructuring. Also monitoring $MYNZ...
CapitalPulse77 - 2 days ago

Way oversold

Just over reaction at the moment. It generates money and there is too many projects on the table. glta dyodd
ecolo101 - 5 days ago

RE:Maybe $25

Just a question,  If you buy PFE on the Canadian NEO exchange, are you still eligible to receive dividends? and in US $$.  If...
ozkan123 - 9 days ago

Well! It happens

Kennedy Junior got the head of the health department....ouch Just Watch him over the next year, hopefully somebody can find a best...
ecolo101 - 9 days ago
View more Bullboard ››

Western Metallica Resources Corp.

Western Metallica Resources Corp.

Western Metallica Resources Corp. is a Canada-based mineral exploration company with five mineral assets across Peru and ...
View More »